Novel Insights into the Role of HDL-Associated Sphingosine-1-Phosphate in Cardiometabolic Diseases
Diarte-Añazco, E. M. G (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular)
Méndez Lara, Karen Alejandra (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular)
Pérez Pérez, Antonio (Institut d'Investigació Biomèdica Sant Pau)
Alonso Pedrol, Núria (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Blanco Vaca, Francisco (Institut d'Investigació Biomèdica Sant Pau)
Julve i Gil, Josep (Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas)

Date:	2019
Abstract:	Sphingolipids are key signaling molecules involved in the regulation of cell physiology. These species are found in tissues and in circulation. Although they only constitute a small fraction in lipid composition of circulating lipoproteins, their concentration in plasma and distribution among plasma lipoproteins appears distorted under adverse cardiometabolic conditions such as diabetes mellitus. Sphingosine-1-phosphate (S1P), one of their main representatives, is involved in regulating cardiomyocyte homeostasis in different models of experimental cardiomyopathy. Cardiomyopathy is a common complication of diabetes mellitus and represents a main risk factor for heart failure. Notably, plasma concentration of S1P, particularly high-density lipoprotein (HDL)-bound S1P, may be decreased in patients with diabetes mellitus, and hence, inversely related to cardiac alterations. Despite this, little attention has been given to the circulating levels of either total S1P or HDL-bound S1P as potential biomarkers of diabetic cardiomyopathy. Thus, this review will focus on the potential role of HDL-bound S1P as a circulating biomarker in the diagnosis of main cardiometabolic complications frequently associated with systemic metabolic syndromes with impaired insulin signaling. Given the bioactive nature of these molecules, we also evaluated its potential of HDL-bound S1P-raising strategies for the treatment of cardiometabolic disease.
Grants:	Agència de Gestió d'Ajuts Universitaris i de Recerca FI-DGR2014 Instituto de Salud Carlos III PI17-00232 Instituto de Salud Carlos III PI17-01362 Instituto de Salud Carlos III PI18/00164 Instituto de Salud Carlos III CPII18/00004 Ministerio de Economía, Industria y Competitividad RED2018-102799-T
Note:	Altres ajuts: Fundació La Marató de TV3 2015 (20152431) (to F. B.-V.) and 2016 (201602.30.31) (to N.A. and J.J.).
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	Sphingolipids ; Apolipoprotein M ; Diabetes mellitus ; Insulin signaling ; Cardiac function ; Cardiomyocyte homeostasis ; Heart failure
Published in:	International journal of molecular sciences, Vol. 20 (december 2019) , ISSN 1422-0067

DOI: 10.3390/ijms20246273
PMID: 31842389

32 p, 3.4 MB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP)
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut de Recerca Sant Pau
Articles > Research articles
Articles > Published articles